A randomized, double-blind, placebo-controlled trial of Abaloparatide men with osteoporosis at high risk for fracture
Phase of Trial: Phase III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Abaloparatide (Primary)
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Radius Health Inc.
- 21 Nov 2017 New trial record
- 02 Nov 2017 According to Radius media release,the compnay expect to initiate this trial in the first quarter of 2018.
- 02 Nov 2017 According to Radius media releas, the compnay has received an agreement with the FDA on the design of this trial which, if successful, will form the basis of an sNDA seeking to expand the use of TYMLOS to treat men with osteoporosis at high risk for fracture.